{"title":"深部脑刺激在多发性硬化震颤中的应用及其新靶点综述。","authors":"Zengrui Zhang, Haiyan Tang, Yang Li, Ying Tan","doi":"10.2147/TCRM.S505015","DOIUrl":null,"url":null,"abstract":"<p><p>Multiple sclerosis (MS) tremors, which are a common cause of disability, do not always respond to pharmacological treatment. Contrastingly, deep brain stimulation (DBS) in the thalamic or subthalamic areas (especially in the zona incerta, ZI) has prompted a response in suppressing MS tremors. In this study, we searched the relevant literature to further investigate the positive and negative effects of using DBS planted in different brain areas to suppress MS tremors. The unique effects of GABAergic agents from the ZI pertain to both the basal ganglia thalamocortical and cerebellar thalamocortical loops, in addition to the brain stem motor effector, where tremor oscillation may be transmitted. From this, the ZI is an effective target for ameliorating MS tremors through surgical treatment. Stimulation of the ZI, even bilaterally, could better control MS tremors, and with fewer side effects than targeting the thalamic area. Thus, the ZI is a promising target for regulating MS tremors. This review on MS tremor suppression will help to further understand the benefits of DBS on the ZI compared to DBS on the thalamic area in terms of managing MS tremors.</p>","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"21 ","pages":"441-454"},"PeriodicalIF":2.8000,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11974577/pdf/","citationCount":"0","resultStr":"{\"title\":\"The Application of Deep Brain Stimulation on Multiple Sclerosis Tremors and the Emerging Targets: A Mini-Review.\",\"authors\":\"Zengrui Zhang, Haiyan Tang, Yang Li, Ying Tan\",\"doi\":\"10.2147/TCRM.S505015\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Multiple sclerosis (MS) tremors, which are a common cause of disability, do not always respond to pharmacological treatment. Contrastingly, deep brain stimulation (DBS) in the thalamic or subthalamic areas (especially in the zona incerta, ZI) has prompted a response in suppressing MS tremors. In this study, we searched the relevant literature to further investigate the positive and negative effects of using DBS planted in different brain areas to suppress MS tremors. The unique effects of GABAergic agents from the ZI pertain to both the basal ganglia thalamocortical and cerebellar thalamocortical loops, in addition to the brain stem motor effector, where tremor oscillation may be transmitted. From this, the ZI is an effective target for ameliorating MS tremors through surgical treatment. Stimulation of the ZI, even bilaterally, could better control MS tremors, and with fewer side effects than targeting the thalamic area. Thus, the ZI is a promising target for regulating MS tremors. This review on MS tremor suppression will help to further understand the benefits of DBS on the ZI compared to DBS on the thalamic area in terms of managing MS tremors.</p>\",\"PeriodicalId\":22977,\"journal\":{\"name\":\"Therapeutics and Clinical Risk Management\",\"volume\":\"21 \",\"pages\":\"441-454\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-04-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11974577/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutics and Clinical Risk Management\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/TCRM.S505015\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutics and Clinical Risk Management","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/TCRM.S505015","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
The Application of Deep Brain Stimulation on Multiple Sclerosis Tremors and the Emerging Targets: A Mini-Review.
Multiple sclerosis (MS) tremors, which are a common cause of disability, do not always respond to pharmacological treatment. Contrastingly, deep brain stimulation (DBS) in the thalamic or subthalamic areas (especially in the zona incerta, ZI) has prompted a response in suppressing MS tremors. In this study, we searched the relevant literature to further investigate the positive and negative effects of using DBS planted in different brain areas to suppress MS tremors. The unique effects of GABAergic agents from the ZI pertain to both the basal ganglia thalamocortical and cerebellar thalamocortical loops, in addition to the brain stem motor effector, where tremor oscillation may be transmitted. From this, the ZI is an effective target for ameliorating MS tremors through surgical treatment. Stimulation of the ZI, even bilaterally, could better control MS tremors, and with fewer side effects than targeting the thalamic area. Thus, the ZI is a promising target for regulating MS tremors. This review on MS tremor suppression will help to further understand the benefits of DBS on the ZI compared to DBS on the thalamic area in terms of managing MS tremors.
期刊介绍:
Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines, therapeutic and surgical interventions in all clinical areas.
The journal welcomes submissions covering original research, clinical and epidemiological studies, reviews, guidelines, expert opinion and commentary. The journal will consider case reports but only if they make a valuable and original contribution to the literature.
As of 18th March 2019, Therapeutics and Clinical Risk Management will no longer consider meta-analyses for publication.
The journal does not accept study protocols, animal-based or cell line-based studies.